Connect with Us
602 Park Point Drive, Suite 225, Golden, CO 80401 – +1 303.495.2073
© 2024 Medical Affairs Professional Society (MAPS). All Rights Reserved Worldwide.
This article seeks to outline the different aspects of MA strategy and launch excellence specific to supporting the development and launch of treatments targeting rare diseases and to provide a roadmap for MA teams and organizations undertaking this planning. While each rare disease is different and will require a tailored approach, this roadmap provides broad considerations for MA organizations.
In Q&A format, this article summarizes key learnings from a MAPS 2022 Global Annual Meeting panel presented by the Medical Strategy FAWG.
This webinar will be covering:
1.   Looking into the future of MA in Japan
a.   How to engage more with Patients/Patient Advocacy groups
b.   How to bring more value to customers, scientific leaders and health systems
c.    How to better engage academia and health authority group through scientific exchange
2.   Opportunities for improving effectiveness
a.   Differentiation of MSL and Medical Rep roles- how are companies differentiating despite the regulations?
This paper synthesizes the views of senior global Medical Affairs leaders to provide a unified vision for the future of Medical Affairs. As such, this document represents the first consensus position by executives in Medical Affairs of our evolving roles, activities, and value in society, industry, teams and as individuals (detailing each in turn). By 2030, Medical Affairs will solidify its transition from executional to strategic, and the function will come to represent the voice of the patient within industry. We will not only disseminate evidence but also lead evidence generation activities that inform the real-world use of marketed and emerging treatments. Also in this time frame, we will solidify the role of Medical Affairs as industry’s external earpiece, gleaning insights from our interactions with the health care ecosystem that drive understanding of patient, payer, and provider needs and opinions. Throughout this evolution, the true north of Medical Affairs remains the same: to ensure that our science and technologies benefit patients.
MAPS members represent the full range of Medical Affairs professionals, from those leading or working in large organizations, to those tasked with starting a Medical Affairs function at startup or emerging organizations. Here, MAPS speaks with Lobna Salem, Regional Chief Medical officer Developed Markets& Japan Australia and New Zealand at Viatris, about the process of building Medical Affairs from scratch.
Medical Affairs is a function within the biopharmaceutical, consumer healthcare, and MedTech industries that sits alongside other functions including Research & Development (R&D) and Commercial as one of the strategic pillars of the industry. R&D develops new drugs, devices and diagnostics; Commercial markets and sells these products; and Medical Affairs generates and communicates data that help healthcare professionals (HCPs), payors, policy makers and others make informed decisions that ensure the best use of treatments to benefit patients. In this way, Medical Affairs plays a vital role in providing scientific evidence and understanding to appropriately change clinical practice.
Just as there are many roles within R&D and Commercial, individuals working within Medical Affairs are responsible for many activities, especially including the following:
At the MAPS 2022 Global Annual Meeting, MAPS sits down to chat with José Borbolla, Global Executive Medical Director at Esai, and Augusto Grinspan, VP Medical Affairs and Head LATAM with Merck KGaA about developments in the practice and direction of Medical Affairs in Latin America. Augusto and José are also co-chairs of the MAPS Latin America Chapter.
This webinar will analyze the current state of Medical Affairs in Japan, highlight progress made and provide suggestions on what we can do together to make Medical Affairs in Japan even more effective.
This webinar will be covering:
1.   MA in Japan today: progress and highlights
a.   Leadership requirements in Japan to bring MA to the next level
b.   MA has become more strategic across all companies
c.    What are the competencies required to succeed?
2.   Looking into the future of MA in Japan
a.   How to engage more with Patients/Patient Advocacy groups
b.   How to bring more value to customers, scientific leaders and health systems
c.    How to better engage academia and health authority group through scientific exchange
3.   Opportunities for improving effectiveness
a.   Differentiation of MSL and Medical Rep roles- how are companies differentiating despite the regulations?
As Medical Affairs professionals, it's easy to focus on the tasks that are right in front of us everyday. In this interview with Monica de Abadal, SVP and Head of Medical Affairs, North America we sat down at the MAPS 2022 Global Annual Meeting to take a step back. Here is how Medical Affairs benefits patients and society. Watch the full interview here.
This podcast, recorded at the MAPS 2022 Global Annual Meeting, addresses the unique position of Medical Affairs in the rare disease space & how our work in this area is essential for patient benefit.
602 Park Point Drive, Suite 225, Golden, CO 80401 – +1 303.495.2073
© 2024 Medical Affairs Professional Society (MAPS). All Rights Reserved Worldwide.